Bepreve

GPTKB entity

Statements (62)
Predicate Object
gptkbp:instanceOf ophthalmic solution
gptkbp:activeDuring gptkb:bepotastine_besilate
gptkbp:approves gptkb:FDA
gptkbp:availableFormats 0.7% solution
gptkbp:clinicalTrials gptkb:American_Academy_of_Ophthalmology
Phase III
ophthalmology
positive efficacy results
NCT01234567
Efficacy in allergic conjunctivitis
improved eye comfort
reduces symptoms of allergic conjunctivitis
gptkbp:colors clear
gptkbp:contraindication blurred vision
burning sensation
taste disturbance
hypersensitivity_to_bepotastine
gptkbp:dosageForm solution
1 drop in affected eye(s) twice daily
gptkbp:drugInterdiction true
none reported
H1 receptor antagonist
topical absorption
gptkbp:expansion isotonic
gptkbp:expirationDate check packaging
gptkbp:exportMarkets ongoing monitoring
gptkbp:formulation eye drops
preservative-free
gptkbp:hasPopulation adults and children over 2 years
gptkbp:healthcare important for effectiveness
provided by healthcare professionals
consult healthcare provider
gptkbp:historical_analysis Long-term safety study
https://www.w3.org/2000/01/rdf-schema#label Bepreve
gptkbp:insuranceAccepted may be covered
gptkbp:isCriticizedFor low viscosity
gptkbp:label FDA_approved_labeling
gptkbp:lastProduced 2011
gptkbp:mandates seasonal allergic conjunctivitis
gptkbp:manufacturer gptkb:Bausch_+_Lomb
gptkbp:marketedAs gptkb:United_States
gptkbp:marketSegment available
gptkbp:offers varies by pharmacy
gptkbp:packaging bottle
5 mL
gptkbp:patentStatus patented
gptkbp:regulatoryCompliance FDA_approval_process
gptkbp:research pharmaceutical company
gptkbp:route topical
gptkbp:safetyFeatures adverse event reporting
generally well tolerated
not for injection
gptkbp:shelfLife 24 months
gptkbp:sideEffect headache
dry eyes
eye irritation
gptkbp:storage room temperature
gptkbp:triggerType inhibits histamine release
gptkbp:trimLevels 6.0 to 7.0
gptkbp:type no
gptkbp:usedFor treatment of allergic conjunctivitis
gptkbp:uses shake well before use